Innate Pharma SA（IPHA）股票分析

AI 分析 of Innate Pharma SA (IPHA)

持有

Currently, Innate Pharma SA (IPHA) is not a strong buy. The stock is trading at $1.40, significantly below its 52-week high of $2.71, indicating a potential for recovery but also substantial risk. The RSI is at 30.25, suggesting it is oversold, which could indicate a buying opportunity if the fundamentals improve. However, the company reported a gross margin of -889.87% in Q1 2026, reflecting severe financial distress, and a net income loss of €27.6 million, which raises concerns about its sustainability. The main risk is the upcoming earnings report on November 5, 2026, which could further impact the stock's performance depending on the results.

估值指標

Innate Pharma SA（IPHA）目前預期本益比為 0.00，5 年平均預期本益比為 -1.86。

預期本益比

合理

5 年均值 P/E

-1.86

目前P/E

0.00

高估

11.82

低估

-15.54

預期 EV/EBITDA

高估

5 年均值 EV/EBITDA

-4.93

目前EV/EBITDA

-0.45

高估

-1.59

低估

-8.27

預期股價營收比

低估

5 年均值 P/S

3.71

目前P/S

1.38

高估

5.14

低估

2.27

持有 IPHA 的大戶

B

Bpifrance Participations SA

+ 持有IPHA

+7.64%

3個月報酬率

IPHA 常見問題 —— 由 Alphio AI 解答

Innate Pharma SA is a France-based biopharmaceutical company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. It works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. It also has a multi-product partnership with AstraZeneca. It operates in the Healthcare sector.

Currently, Innate Pharma SA (IPHA) is not a strong buy. The stock is trading at $1.40, significantly below its 52-week high of $2.71, indicating a potential for recovery but also substantial risk. The RSI is at 30.25, suggesting it is oversold, which could indicate a buying opportunity if the fundamentals improve. However, the company reported a gross margin of -889.87% in Q1 2026, reflecting severe financial distress, and a net income loss of €27.6 million, which raises concerns about its sustainability. The main risk is the upcoming earnings report on November 5, 2026, which could further impact the stock's performance depending on the results.